Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 18/20 | 0.66 |
| ▸ | DPP8 | Q6V1X1 | 13/20 | 0.66 |
| ▸ | DPP9 | Q86TI2 | 13/20 | 0.66 |
| ▸ | DPP7 | Q9UHL4 | 13/20 | 0.66 |
| ▸ | FAP | Q12884 | 10/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6437755 | 0.84 | DPP4 (0.69) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL6437757 | 0.84 | DPP4 (0.69) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL8881323 | 0.81 | DPP4 (0.55) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL6439142 | 0.79 | DPP4 (0.61) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL6439141 | 0.79 | DPP4 (0.61) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL10961420 | 0.77 | DPP4 (0.59) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL8366666 | 0.77 | DPP4 (0.59) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL14311579 | 0.76 | DPP7 (0.61) | DPP4DPP8DPP9DPP7FAP | |
| Hydrochloric Acid SCHEMBL6436808 | 0.76 | DPP4 (0.58) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL10512195 | 0.76 | ACE (0.57) | DPP4DPP8DPP9DPP7FAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6797710-B2 | CARDIOVASCULAR DISORDERS; SERINE PROTEASE INHIBITOR; ADMINISTERING BY MOUTH; BIOAVAILABILITY | AKZO NOBEL N.V. (NL) | 2004-09-28 | — | — | US | disclosed |
| US-20030130270-A1 | Heterocyclic derivatives and their use as antithrombotic agents | MERCK SHARP & DOHME B.V. (NL) | 2003-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130270-A1 | Heterocyclic derivatives and their use as antithrombotic agents | F2, F12, VKORC1 | DPP4 1413/4885DPP8 1777/4885DPP9 1063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.